PubRank

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

Clinical Trial ID NCT00074425

PubWeight™ 17.64‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00074425

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011 2.86
2 Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008 2.25
3 Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004 1.97
4 Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003 1.95
5 Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 2008 1.71
6 Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr 2001 1.63
7 Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 2001 1.57
8 Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr 2013 1.33
9 Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr 2003 1.23
10 Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis 2014 0.96
11 Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis 2012 0.92
12 HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One 2014 0.91
13 Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035). AIDS Behav 2014 0.88
14 HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sex Transm Infect 2014 0.88
15 Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sex Transm Dis 2014 0.88
16 Microflora changes with the use of a vaginal microbicide. Sex Transm Dis 2002 0.86
17 Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception 2015 0.82
18 An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. J Acquir Immune Defic Syndr 2016 0.82
19 Impact of targeted counseling on reported vaginal hygiene practices and bacterial vaginosis: the HIV Prevention Trials Network 035 study. Int J STD AIDS 2016 0.78
Next 100